• Home
  • Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

NASDAQ: ONTX was devalued by Zacks  from a “purchase” ranking to a “hold” ranking in a research note provided to financiers on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It focuses on discovering as well as establishing tiny particle drug prospects to treat cancer. The Company‘s products under different stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research experts additionally just recently discussed the company. Noble Financial editioned a “buy” score and released a $11.00 rate purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and also set a “get” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving average price of $2.90 and a two-hundred day moving ordinary cost of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) incomes per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and a negative net margin of 8,294.27%. The firm had revenue of $0.06 million during the quarter, compared to the consensus price quote of $0.06 million. Throughout the exact same quarter in the prior year, the firm posted ($ 0.45) EPS. En masse, research experts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the present year.

A variety of hedge funds have actually just recently bought and sold shares of ONTX. GSA Funding Partners LLP got a new placement in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Administration LP got a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC got a new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and various other institutional capitalists own 13.36% of the company’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the recognition and also development of oncology therapeutics. It concentrates on discovering and also establishing small particle drug prospects to deal with cancer cells. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a free copy of the Zacks research report on Onconova Therapeutics (ONTX).

For more details concerning research offerings from Zacks Investment Research, browse through Zacks.com.

This immediate information alert was created by narrative science innovation as well as economic data from Market in order to offer viewers with the fastest and most exact reporting. This tale was reviewed by Market’s editorial group before publication. 



Before you take into consideration Onconova Therapeutics, you’ll want to hear this.

Market keeps an eye on Wall Street’s top-rated and finest performing research analysts as well as the stocks they recommend to their customers every day. Market has actually determined the five stocks that top analysts are quietly whispering to their customers to purchase now before the more comprehensive market catches on … and also Onconova Therapeutics wasn’t on the listing.

While Onconova Therapeutics presently has a “Buy” ranking among experts, top-rated experts think these 5 stocks are much better buys.